SCA 40

Drug Profile

SCA 40

Latest Information Update: 20 Jun 2001

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Antiasthmatics; Bronchodilators; Muscle relaxants
  • Mechanism of Action Potassium channel agonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 20 Jun 2001 No-Development-Reported for Asthma in European Union (Unknown route)
  • 07 Mar 1997 Novartis is developing SCA 40 in the European Union
  • 09 Feb 1996 Preclinical development for Asthma in European Union (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top